Skip to main content
Clinical Trials/CTRI/2014/09/005061
CTRI/2014/09/005061
Recruiting
Phase 1

A study of safety, efficacy and refractive outcomes of MEL 90 excimer laser platform - MEL 90

ETHRADHAMA SUPERSPECIALITY EYE HOSPITA0 sites100 target enrollmentTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Health Condition 1: null- Patients with Myopia, Hypermetropia and Astigmatism undergoing treatment on the MEL 90 excimer laser platform
Sponsor
ETHRADHAMA SUPERSPECIALITY EYE HOSPITA
Enrollment
100
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
ETHRADHAMA SUPERSPECIALITY EYE HOSPITA

Eligibility Criteria

Inclusion Criteria

  • Any gender, 21 to 40 years of age
  • Stable corneal conditions within the last 12 months
  • Stable refraction since past 12 months ( \<0\.5D change within past 12 months)
  • Healthy ocular surface with stable tear film
  • Discontinuation of Soft contact lenses 1 week, and rigid contact lenses 3 weeks prior to surgery
  • For myopia correction, myopia upto \-10 Diopters
  • For hyperopia correction, hyperopia upto \+ 3 Diopters
  • For astigmatic correction, astigmatism upto 3 Diopters

Exclusion Criteria

  • Thin corneas (Corneal pachymetry \<480u)
  • Steep corneas Kmax \>48 D
  • Keratoconus suspects or frank keratoconus
  • Moderate to severe dry eye (Shirmers1 \<10 mm)
  • Socket / globe /lid anomalies â?? very deep set eyes, nanophthalmos
  • Severe meibomian gland disease, lid abnormalities
  • Severe atopy
  • Contact lens overuse
  • Pregnant and nursing mother
  • Autoimmune disorders

Outcomes

Primary Outcomes

Not specified

Similar Trials